Specific cell-permeable inhibitor of proteasome trypsin-like sites selectively sensitizes myeloma cells to bortezomib and carfilzomib

Chemistry and Biology

Volumn 18, Issue 5, 2011, Pages 608-618

  Mirabella, Anne C ^a,b   Pletnev, Alexandre A ^a,c   Downey, Sondra L ^a   Florea, Bogdan I ^d   Shabaneh, Tamer B ^a   Britton, Matthew ^a,b   Verdoes, Martijn ^d   Filippov, Dmitri V ^d   Overkleeft, Herman S ^d   Kisselev, Alexei F ^a  

^a DARTMOUTH MEDICAL SCHOOL   (United States)

^b University of Bath   (United Kingdom)

^c Dartmouth College   (United States)

^d NETHERLANDS PROTEOMICS CENTRE   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BORONIC ACID DERIVATIVE; BORTEZOMIB; CARFILZOMIB; OLIGOPEPTIDE; PROTEASOME; PROTEINASE INHIBITOR; PYRAZINE DERIVATIVE; TRYPSIN;

ARTICLE; CELL MEMBRANE PERMEABILITY; CHEMISTRY; DRUG ANTAGONISM; DRUG EFFECT; ENZYME ACTIVE SITE; HUMAN; METABOLISM; MULTIPLE MYELOMA; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; BORONIC ACIDS; CATALYTIC DOMAIN; CELL LINE, TUMOR; CELL MEMBRANE PERMEABILITY; HUMANS; MULTIPLE MYELOMA; OLIGOPEPTIDES; PROTEASE INHIBITORS; PROTEASOME ENDOPEPTIDASE COMPLEX; PYRAZINES; TRYPSIN;

MAMMALIA;

EID: 79957477617     PISSN: 10745521     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.chembiol.2011.02.015     Document Type: Article

References (38)

1. J. Adams The development of proteasome inhibitors as anticancer drugs Cancer Cell 5 2004 417 421 (Pubitemid 38610244)
2. M. Altun, P.J. Galardy, R. Shringarpure, T. Hideshima, R. LeBlanc, K.C. Anderson, H.L. Ploegh, and B.M. Kessler Effects of PS-341 on the activity and composition of proteasomes in multiple myeloma cells Cancer Res. 65 2005 7896 7901 (Pubitemid 41297267)
3. P. Benes, V. Vetvicka, and M. Fusek Cathepsin D: many functions of one aspartic protease Crit. Rev. Oncol. Hematol. 68 2008 12 28
4. C.R. Berkers, M. Verdoes, E. Lichtman, E. Fiebiger, B.M. Kessler, K.C. Anderson, H.L. Ploegh, H. Ovaa, and P.J. Galardy Activity probe for in vivo profiling of the specificity of proteasome inhibitor bortezomib Nat. Methods 2 2005 357 362 (Pubitemid 41130981)
5. M. Britton, M.M. Lucas, S.L. Downey, M. Screen, A.A. Pletnev, M. Verdoes, R.A. Tokhunts, O. Amir, A.L. Goddard, and P.M. Pelphrey Selective inhibitor of proteasome's caspase-like sites sensitizes cells to specific inhibition of chymotrypsin-like sites Chem. Biol. 16 2009 1278 1289
6. P. Cascio, C. Hilton, A. Kisselev, K. Rock, and A. Goldberg 26S proteasomes and immunoproteasomes produce mainly N-extended versions of an antigenic peptide EMBO J. 20 2001 2357 2366 (Pubitemid 32452853)
7. D. Chauhan, L. Catley, G. Li, K. Podar, T. Hideshima, M. Velankar, C. Mitsiades, N. Mitsiades, H. Yasui, and A. Letai A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from bortezomib Cancer Cell 8 2005 407 419 (Pubitemid 41579835)
8. S.D. Demo, C.J. Kirk, M.A. Aujay, T.J. Buchholz, M. Dajee, M.N. Ho, J. Jiang, G.J. Laidig, E.R. Lewis, and F. Parlati Antitumor activity of PR-171, a novel irreversible inhibitor of the proteasome Cancer Res. 67 2007 6383 6391 (Pubitemid 47037522)
9. B.I. Florea, M. Verdoes, N. Li, W.A. van der Linden, P.P. Geurink, H. van den Elst, T. Hofmann, A. de Ru, P.A. van Veelen, and K. Tanaka Activity-based profiling reveals reactivity of the murine thymoproteasome-specific subunit beta5t Chem. Biol. 17 2010 795 801
10. P.P. Geurink, N. Liu, M.P. Spaans, S.L. Downey, A.M. van den Nieuwendijk, G.A. van der Marel, A.F. Kisselev, B.I. Florea, and H.S. Overkleeft Incorporation of fluorinated phenylalanine generates highly specific inhibitor of proteasome's chymotrypsin-like sites J. Med. Chem. 53 2010 2319 2323
11. M. Groettrup, and G. Schmidtke Selective proteasome inhibitors: modulators of antigen presentation? Drug Discov. Today 4 1999 63 71 (Pubitemid 29295387)
12. M. Groll, and R. Huber Inhibitors of the eukaryotic 20S proteasome core particle: a structural approach Biochim. Biophys. Acta 1695 2004 33 44 (Pubitemid 39574966)
13. M. Groll, K.B. Kim, N. Kairies, R. Huber, and C.M. Crews Crystal structure of epoxomicin: 20S proteasome reveals a molecular basis for selectivity of alpha beta-epoxyketone proteasome inhibitors J. Am. Chem. Soc. 122 2000 1237 1238 (Pubitemid 30117471)
14. M. Groll, T. Nazif, R. Huber, and M. Bogyo Probing structural determinants distal to the site of hydrolysis that control substrate specificity of the 20S proteasome Chem. Biol. 9 2002 655 662 (Pubitemid 34593046)
15. A.L. Hamilton, J.P. Eder, A.C. Pavlick, J.W. Clark, L. Liebes, R. Garcia-Carbonero, A. Chachoua, D.P. Ryan, V. Soma, and K. Farrell Proteasome inhibition with bortezomib (PS-341): a phase I study with pharmacodynamic end points using a day 1 and day 4 schedule in a 14-day cycle J. Clin. Oncol. 23 2005 6107 6116
16. J.L. Harris, P.B. Alper, J. Li, M. Rechsteiner, and B.J. Backes Substrate specificity of the human proteasome Chem. Biol. 8 2001 1131 1141 (Pubitemid 34029882)
17. B.M. Kessler, D. Tortorella, M. Altun, A.F. Kisselev, E. Fiebiger, B.G. Hekking, H.L. Ploegh, and H.S. Overkleeft Redundancy of proteasomal subunits is revealed by extended peptide-based inhibitors Chem. Biol. 8 2001 913 929
18. H. Kirschke, and B. Wiederanders Cathepsin S and related lysosomal endopeptidases Methods Enzymol. 244 1994 500 511
19. A.F. Kisselev Joining the army of proteasome inhibitors Chem. Biol. 15 2008 419 421 (Pubitemid 351645120)
20. A.F. Kisselev, and A.L. Goldberg Proteasome inhibitors: from research tools to drug candidates Chem. Biol. 8 2001 739 758 (Pubitemid 32752454)
21. A.F. Kisselev, and A.L. Goldberg Measuring activity and inhibition of 26S proteasomes with fluorogenic peptide substrates Methods Enzymol. 398 2005 364 378 (Pubitemid 41578898)
22. A.F. Kisselev, A. Callard, and A.L. Goldberg Importance of different active sites in protein breakdown by 26S proteasomes and the efficacy of proteasome inhibitors varies with the protein substrate J. Biol. Chem. 281 2006 8583 8590
23. E. Kupperman, E.C. Lee, Y. Cao, B. Bannerman, M. Fitzgerald, A. Berger, J. Yu, Y. Yang, F. Bruzzese, and J. Liu Evaluation of the proteasome inhibitor MLN9708 in preclinical models of human cancer Cancer Res. 70 2010 1970 1980
24. G. Loidl, M. Groll, H.J. Musiol, L. Ditzel, R. Huber, and L. Moroder Bifunctional inhibitors of the trypsin-like activity of eukaryotic proteasomes Chem. Biol. 6 1999 197 204 (Pubitemid 29368408)
25. M. Marastoni, A. Baldisserotto, S. Cellini, R. Gavioli, and R. Tomatis Peptidyl vinyl ester derivatives: new class of selective inhibitors of proteasome trypsin-like activity J. Med. Chem. 48 2005 5038 5042 (Pubitemid 41033143)
26. T.A. McCormack, A.A. Cruikshank, L. Grenier, F.D. Melandri, S.L. Nunes, L. Plamondon, R.L. Stein, and L.R. Dick Kinetic studies of the branched chain amino acid preferring peptidase activity of the 20S proteasome: development of a continious assay and inhibition by tripeptide aldehydes and clasto-lactacystin β-lactone Biochemistry 37 1998 7792 7800 (Pubitemid 28248639)
27. L. Meng, R. Mohan, B.H. Kwok, M. Elofsson, N. Sin, and C.M. Crews Epoxomicin, a potent and selective proteasome inhibitor, exhibits in vivo antiinflammatory activity Proc. Natl. Acad. Sci. USA 96 1999 10403 10408 (Pubitemid 29422570)
28. R.A. Moravec, M.A. O'Brien, W.J. Daily, M.A. Scurria, L. Bernad, and T.L. Riss Cell-based bioluminescent assays for all three proteasome activities in a homogeneous format Anal. Biochem. 387 2009 294 302
29. T. Nazif, and M. Bogyo Global analysis of proteasomal substrate specificity using positional-scanning libraries of covalent inhibitors Proc. Natl. Acad. Sci. USA 98 2001 2967 2972 (Pubitemid 32220783)
30. O.A. O'Connor, A.K. Stewart, M. Vallone, C.J. Molineaux, L.A. Kunkel, J.F. Gerecitano, and R.Z. Orlowski A phase 1 dose escalation study of the safety and pharmacokinetics of the novel proteasome inhibitor carfilzomib (PR-171) in patients with hematologic malignancies Clin. Cancer Res. 15 2009 7085 7091
31. H. Ovaa, P.F. van Swieten, B.M. Kessler, M.A. Leeuwenburgh, E. Fiebiger, A.M. van den Nieuwendijk, P.J. Galardy, G.A. van der Marel, H.L. Ploegh, and H.S. Overkleeft Chemistry in living cells: detection of active proteasomes by a two-step labeling strategy Angew. Chem. Int. Ed. Engl. 42 2003 3626 3629 (Pubitemid 37010644)
32. R. Piva, B. Ruggeri, M. Williams, G. Costa, I. Tamagno, D. Ferrero, V. Giai, M. Coscia, S. Peola, and M. Massaia CEP-18770: A novel, orally active proteasome inhibitor with a tumor-selective pharmacologic profile competitive with bortezomib Blood 111 2008 2765 2775
33. H.G. Rammensee, T. Friede, and S. Stevanoviic MHC ligands and peptide motifs: first listing Immunogenetics 41 1995 178 228
34. K.L. Rock, I.A. York, T. Saric, and A.L. Goldberg Protein degradation and the generation of MHC class I-presented peptides Adv. Immunol. 80 2002 1 70 (Pubitemid 34625620)
35. M. Screen, M. Britton, S.L. Downey, M. Verdoes, M.J. Voges, A.E. Blom, P.P. Guerink, M.D. Risseeuw, B.I. Florea, and W.A. van der Linden The nature of pharmacophore influences active site specificity of proteasome inhibitors J. Biol. Chem. 285 2010 40125 40134
36. M. Verdoes, B.I. Florea, V. Menendez-Benito, M.D. Witte, W.A. van der Linden, A.M.C.H. van den Nieuwendijk, T. Hofmann, C. Berkers, F.W.B. van Leeuwen, and T.A. Groothuis A fluorescent broad spectrum proteasome inhibitor for labeling proteasomes in vitro and in vivo Chem. Biol. 13 2006 1217 1226 (Pubitemid 44750733)
37. M. Verdoes, B.I. Florea, U. Hillaert, L.I. Willems, W.A. van der Linden, M. Sae-Heng, D.V. Filippov, A.F. Kisselev, G.A. van der Marel, and H.S. Overkleeft Azido-BODIPY acid reveals quantitative Staudinger-Bertozzi ligation in two-step activity-based proteasome profiling ChemBioChem 9 2008 1735 1738
38. H.J. Zhou, M.A. Aujay, M.K. Bennett, M. Dajee, S.D. Demo, Y. Fang, M.N. Ho, J. Jiang, C.J. Kirk, and G.J. Laidig Design and synthesis of an orally bioavailable and selective peptide epoxyketone proteasome inhibitor (PR-047) J. Med. Chem. 52 2009 3028 3038